Literature DB >> 9574565

Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes.

B D Freimark1, H P Blezinger, V J Florack, J L Nordstrom, S D Long, D S Deshpande, S Nochumson, K L Petrak.   

Abstract

Administration of plasmid/lipid complexes to the lung airways may be associated, in addition to expression of transgene, with a range of other responses. We report here the induction of cytokines and cellular influx in the lung airway following intratracheal administration of an N-[1-(2-3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride/cholesterol/plasmid positively charged complex in mice. We show that 1) the appearance of the Th1-associated cytokines IFN-gamma and IL-12 in bronchoalveolar lavage fluid is caused by unmethylated CpG dinucleotide sequences present within the plasmid, and is enhanced by the lipid formulation; 2) cationic lipids by themselves do not induce IL-12 or IL-12p40; 3) TNF-alpha is rapidly induced by cationic lipids and plasmid/lipid complex, but not by plasmid alone; 4) an acute cellular influx is induced by cationic lipid alone and by a plasmid/lipid complex, but to a much lesser extent by plasmid alone; and 5) plasmid methylation does not influence the degree of inflammatory cell influx. The induction of the innate immune responses by plasmid/lipid complexes may be advantageous to gene therapy of lung diseases. In particular, induction of the Th1 cell-promoting cytokines by plasmid/lipid complexes could, in conjunction with an expressed transgene, be used to modulate immune responses in the lung airways in disease conditions that are deficient in Th1 cell responses or that have a dominant Th2 phenotype. Alternatively, the elimination of immunostimulatory sequences in plasmids may improve the tolerability and/or efficacy of nonviral gene therapy, especially for diseases requiring chronic administration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574565

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Aerosol gene therapy.

Authors:  Ajay Gautam; J Clifford Waldrep; Charles L Densmore
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

Review 3.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 4.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 5.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 6.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

Review 7.  Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors:  Mahmoud Elsabahy; Karen L Wooley
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

8.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

9.  A novel vaccine adjuvant for recombinant flu antigens.

Authors:  Stella Chang; John Warner; Lily Liang; Jeff Fairman
Journal:  Biologicals       Date:  2009-03-12       Impact factor: 1.856

10.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.